Exploring the S Protein of SARS-CoV-2 to Design a Novel Multi-Epitope Vaccine against COVID-19 Based on Immunoinformatics Approaches
Frontiers in Bioscience-Landmark · 2024
DOI: 10.31083/j.fbl2905196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Zhuanqing Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Research Division, Department of Pharmacy, Medical Supplies Centre of PLA General Hospital, 100039 Beijing, China. Hauptthemen laut MEDLINE: COVID-19 Vaccines, Spike Glycoprotein, Coronavirus, SARS-CoV-2, Epitopes, T-Lymphocyte. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Developing a novel COVID-19 multi-epitope vaccine (CoVMEV) is essential to containing the SARS-CoV-2 pandemic.
Methods
The virus’s immunodominant B and T cell epitopes from the S protein were found and joined to create the CoVMEV. Bioinformatics techniques were used to investigate the secondary and tertiary structures, as well as the physical and chemical properties of CoVMEV.
Results
CoVMEV exhibited high antigenicity and immunogenicity scores, together with good water solubility and stability. Toll-like receptor 2 (TLR2) and toll-like receptor4 (TLR4), which are critical in triggering immunological responses, were also strongly favoured by CoVMEV. Molecular dynamics simulation and immune stimulation studies revealed that CoVMEV effectively activated T and B lymphocytes, and increased the number of active CD8+ T cells than similar vaccines.
Conclusion
CoVMEV holds promise as a potential vaccine candidate for COVID-19, given its robust immunogenicity, stability, antigenicity, and capacity to stimulate a strong immune response. This study presents a significant design concept for the development of peptidyl vaccines targeting SARS-CoV-2. Further investigation and clinical trials will be crucial in assessing the efficacy and safety of CoVMEV as a potential vaccine for COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Sciences Research Division, Department of Pharmacy, Medical Supplies Centre of PLA General Hospital, 100039 Beijing, China.
- Department of Pharmacy, The No. 944 Hospital of Joint Logistic Support Force of PLA, 735099 Jiuquan, Gansu, China.
- Medical School of Chinese PLA, 100016 Beijing, China.
- Department of Pharmacy, Air Force Logistics University, 221000 Xuzhou, Jiangsu, China.
- Department of Pharmacy, Chinese People's Armed Police Force Hospital of Beijing, 100018 Beijing, China.
- Medical Supplies Centre of PLA General Hospital, 100039 Beijing, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, Z., Shi, H., Gong, H., Sun, Q., Yang, S., Zhang, Y., Shi, Z., Xia, Z., Huang, S., Yao, S., & Xu, F. (2024). Exploring the S Protein of SARS-CoV-2 to Design a Novel Multi-Epitope Vaccine against COVID-19 Based on Immunoinformatics Approaches. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2905196
Vancouver
Huang Z, Shi H, Gong H, Sun Q, Yang S, Zhang Y, et al. Exploring the S Protein of SARS-CoV-2 to Design a Novel Multi-Epitope Vaccine against COVID-19 Based on Immunoinformatics Approaches. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2905196
BibTeX
@article{Huang2024,
author = {Huang, Zhuanqing and Shi, Haoyuan and Gong, Hui and Sun, Qi and Yang, Sen and Zhang, Ying and Shi, Zhenwei and Xia, Zhifa and Huang, Songtao and Yao, Shusen and Xu, Fenghua},
title = {Exploring the S Protein of SARS-CoV-2 to Design a Novel Multi-Epitope Vaccine against COVID-19 Based on Immunoinformatics Approaches},
journal = {Frontiers in Bioscience-Landmark},
year = {2024},
doi = {10.31083/j.fbl2905196}
}
EUVIMED